Relevant bibliographies by topics / Chemotherapy-induced febrile neutropenia

Academic literature on the topic 'Chemotherapy-induced febrile neutropenia'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Chemotherapy-induced febrile neutropenia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Chemotherapy-induced febrile neutropenia"

1

Temblett, Paul. "Chemotherapy-induced febrile neutropenia." Clinical Medicine 8, no. 6 (December 1, 2008): 634.1–634. http://dx.doi.org/10.7861/clinmedicine.8-6-634.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Moe, Myat, and Robert Leonard. "Chemotherapy induced febrile neutropenia." Oncology Times 4, no. 3 (March 2007): 21. http://dx.doi.org/10.1097/01434893-200703000-00019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Salako, Omolola, Kehinde Sharafadeen Okunade, Adeoluwa Akeem Adeniji, Gabriel Fagbenro, and Oluwasegun Afolaranmi. "Chemotherapy-induced neutropenia among breast cancer patients presenting to a tertiary hospital in Nigeria." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e12523-e12523. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e12523.

Full text
Abstract:
e12523 Background: Neutropenia and febrile neutropenia are major dose-limiting adverse effects of systemic cancer chemotherapy. It has been associated with significant morbidity and mortality, and high costs of management, and treatment breaks in cancer patients especially in resource-limited environments leading to poorer outcomes. Chemotherapy-induced neutropenia is an established complication of breast cancer treatment, however, there is paucity of information on the exact magnitude of the condition. This study assessed the prevalence of neutropenia and febrile neutropenia, while identifying their associated factors. Methods: A cross-sectional study was conducted among 113 female chemotherapy-naïve breast cancer patients over a two-year period. Sociodemographic, clinical and haematological data was obtained via semi-structured interviews and from medical case files. Blood samples for complete blood count parameters were collected after each course of chemotherapy. The National Cancer Institute Common Terminology CTCAE version 4.03 was used to assess febrile neutropenia, neutropenia and its severity. Results: The prevalence of neutropenia and febrile neutropenia among the patients was 31.9% and 5.3% respectively. Throughout all courses of chemotherapy, there were neutropenic episodes 11.4% (57/502) with mild neutropenia 6.6%, moderate 3.4% and severe 1.4%. Prevalence of neutropenia decreased with increasing chemotherapy courses, with prevalence after first course being 14.2% and last course 4.9%. Associated risk factors for developing neutropenia include increasing age ( p = 0.014), ECOG performance score > 1 at presentation (p = 0.033) and presence of bone metastasis (p = 0.002). Conclusions: One in three breast cancer patients developed neutropenia while on chemotherapy. The use of prophylactic G-CSF after each course of chemotherapy should be a routine practice, especially among elderly patients, unstable patients, and those with bone metastasis.
APA, Harvard, Vancouver, ISO, and other styles
4

Strojnik, Ksenija, Ksenija Mahkovic-Hergouth, Barbara Jezersek Novakovic, and Bostjan Seruga. "Outcome of severe infections in afebrile neutropenic cancer patients." Radiology and Oncology 50, no. 4 (December 1, 2016): 442–48. http://dx.doi.org/10.1515/raon-2016-0011.

Full text
Abstract:
Abstract Background In some neutropenic cancer patients fever may be absent despite microbiologically and/or clinically confirmed infection. We hypothesized that afebrile neutropenic cancer patients with severe infections have worse outcome as compared to cancer patients with febrile neutropenia. Patients and methods We retrospectively analyzed all adult cancer patients with chemotherapy-induced neutropenia and severe infection, who were admitted to the Intensive Care Unit at our cancer center between 2000 and 2011. The outcome of interest was 30-day in-hospital mortality rate. Association between the febrile status and in-hospital mortality rate was evaluated by the Fisher’s exact test. Results We identified 69 episodes of severe neutropenic infections in 65 cancer patients. Among these, 9 (13%) episodes were afebrile. Patients with afebrile neutropenic infection presented with hypotension, severe fatigue with inappetence, shaking chills, altered mental state or cough and all of them eventually deteriorated to severe sepsis or septic shock. Overall 30-day in-hospital mortality rate was 55.1%. Patients with afebrile neutropenic infection had a trend for a higher 30-day in-hospital mortality rate as compared to patients with febrile neutropenic infection (78% vs. 52%, p = 0.17). Conclusions Afebrile cancer patients with chemotherapy-induced neutropenia and severe infections might have worse outcome as compared to cancer patients with febrile neutropenia. Patients should be informed that severe neutropenic infection without fever can occasionally occur during cancer treatment with chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
5

Marshall, E., and H. Innes. "Chemotherapy induced febrile neutropenia: management and prevention." Clinical Medicine 8, no. 4 (August 1, 2008): 448–51. http://dx.doi.org/10.7861/clinmedicine.8-4-448.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Korpelainen, Sini, Carina Intke, Sari Hämäläinen, Esa Jantunen, Auni Juutilainen, and Kari Pulkki. "Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia." Disease Markers 2017 (2017): 1–8. http://dx.doi.org/10.1155/2017/9805609.

Full text
Abstract:
Objective. Elevated levels of a cell surface glycoprotein, soluble cluster of differentiation 14 (sCD14), have been observed in patients with sepsis. Only scarce data are available on sCD14 in hematological patients with chemotherapy-induced febrile neutropenia. The study aim was to investigate sCD14 as an early biomarker in febrile neutropenia after intensive chemotherapy to detect a rapidly deteriorating clinical course early enough to avoid serious infectious complications.Patients and Methods. This prospective study included 87 adult hematological patients at the start of febrile neutropenia after intensive chemotherapy for acute myeloid leukemia or after autologous stem cell transplantation. The study endpoints were septic shock, severe sepsis, and positive blood culture findings. sCD14 was analyzed from day 0 to day 2, and its prognostic capacity was compared to that of C-reactive protein and procalcitonin.Results. Plasma level of sCD14 predicted the development of septic shock on day 1 (p=0.001) and day 2 but not the development of severe sepsis or blood culture positivity in hematological patients with chemotherapy-induced febrile neutropenia.Conclusions. Soluble CD14 did not predict an overall complicated course at the early stages of febrile neutropenia. However, it was helpful in predicting the progression of the clinical course of neutropenic fever to septic shock.
APA, Harvard, Vancouver, ISO, and other styles
7

Murtaza, Hafiz Muhammad, Samra Maryam, Muhammad Shaheen Iqbal, Tariq Ghafoor, Aamir Aslam Awan, and Naeem Farid. "Chemotherapy Induced Neutropenic Fever and Its Response to Empirical Antimicrobial Therapy." Pakistan Armed Forces Medical Journal 72, SUPPL-2 (June 2, 2022): S172–77. http://dx.doi.org/10.51253/pafmj.v72isuppl-2.3079.

Full text
Abstract:
Objective: To find out the frequency of chemotherapy-induced febrile neutropenia (FN) in children diagnosed with Acute Lymphoblastic Leukemia (ALL) and its response to empirical antibiotic therapy. Study Design: Cross-sectional study. Place and Duration of Study: Department of Peadiatric Oncology, Combined Military Hospital, Rawalpindi Pakistan, from Nov 2017 to Oct 2018. Methodology: Newly diagnosed pediatric patients suffering from acute lymphoblastic leukemia between 1 to 15 years of age were included. All patients were treated with chemotherapy according to the United Kingdom National Randomized Trial for Children and Young adults with Acute Lymphoblastic Leukemia (UKALL) 2011 protocol. Patients with febrile neutropenic (FN) episodes were treated with empirical antimicrobial therapy as per hospital guidelines. Patients ‘response to antimicrobial therapy, blood culture results and related complications were noted. Results: Out of a total 77 patients, 45 (58.4%) had 69 episodes of febrile neutropenia (FN), 62 (78.5%) episodes of febrile neutropenia (FN) were started empirical treatment with first-line antibiotics (piperacillin-tazobactam and amikacin) whereas 15 (21.7%) episodes of febrile neutropenia (FN) not responding to the 1st line were shifted to second-line antibiotics (meropenem and amikacin). Mean duration of fever was 4.1 ± 2.8 days on 1st line antibiotic regimen, 2.6 ± 1 days on 2nd line antibiotics and 6.3 ± 3.3 days on combination with antifungal drug. Ten patients received antifungal therapy empirically. Efficacy of the 1st line and the 2nd line was 72.5% and 77% respectively. Staphylococcus aureus was the most frequent organism isolated from blood culture results. During the induction phase, 10 (12.9%) patients..............
APA, Harvard, Vancouver, ISO, and other styles
8

McBride, Ali, Neda Alrawashdh, Trace Bartels, Logan Moore, Daniel Persky, and Ivo Abraham. "Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy." Future Oncology 17, no. 26 (September 2021): 3485–97. http://dx.doi.org/10.2217/fon-2021-0532.

Full text
Abstract:
Aim: To compare the incidence of febrile neutropenia and related outcomes of prophylactic same-day versus next-day pegfilgrastim/pegfilgrastim-cbqv in patients with lymphoma receiving cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone (CHOP)-like chemotherapy. Methods: Retrospective, real-world, single-institution study. Results: 93 patients received 460 cycles of CHOP-like chemotherapy. The incidence of febrile neutropenia and grade 3/4 chemotherapy-induced neutropenia was 5 and 16.5%, respectively. In 401 cycles pegfilgrastim was administered same-day versus 12 cycles next-day. Febrile neutropenia occurred in 17 cycles versus 0 cycles (p = 1.00) and grade 3/4 chemotherapy-induced neutropenia in 65 cycles (16.2%) versus 1 cycle (16.7%; p = 1.00) with same-day versus next-day pegfilgrastim administration, respectively. Conclusion: Pegfilgrastim may be safely administered on the same day as chemotherapy in patients with lymphoma receiving CHOP-like chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
9

Bal, Abhijit M., and Ian M. Gould. "Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia." International Journal of Antimicrobial Agents 29, no. 5 (May 2007): 501–9. http://dx.doi.org/10.1016/j.ijantimicag.2006.11.026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dimitrijević, Jelena, and Marko Stojanović. "Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors." Medicinski podmladak 73, no. 2 (2022): 1–5. http://dx.doi.org/10.5937/mp73-36780.

Full text
Abstract:
Febrile neutropenia is a serious chemotherapy-related adverse event that can lead to complications and death and it could be a significant burden on the organization of the health care system. The risk for febrile neutropenia is determined by chemotherapy-induced myelosuppression and the presence of patient-related risk factors. In the literature, various patient-related risk factors are taken into consideration. It was suggested that the patient age is the one of the most important ones. If the estimated risk for the febrile neutropenia is high, prophylactic use of myeloid growth factors (granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor) is recommended. In patients with solid tumors and lymphomas it was shown that the prophylactic use of myeloid growth factors significantly reduces the incidence of febrile neutropenia, early mortality during chemotherapy and infection-induced mortality. In patients who develop febrile neutropenia, there is less evidence for the therapeutic use of myeloid growth factors compared to prophylactic use, although there is a clear benefit in reducing the time to neutrophil count recovery. There is a clear benefit for hospitalized patients, also, in reducing duration of hospitalization. In patients with febrile neutropenia who have not been previously treated with prophylactic myeloid factors, assessment of risk factors for the complications is advised. In patients with high-risk febrile neutropenia therapeutic use of growth should be considered.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Chemotherapy-induced febrile neutropenia"

1

Lee, Yee Mei. "Predicting chemotherapy-induced febrile neutropenia outcomes in adult cancer patients: an evidence-based prognostic model." Thesis, 2014. http://hdl.handle.net/2440/83772.

Full text
Abstract:
Aims: This thesis explored and examined the clinical factors associated with the outcomes of chemotherapy-induced febrile neutropenia for adult cancer patients and confirms the independent predictive value of these factors. Established as predictors, the factors were used to formulate a multivariable prognostic model to stratify patients according to their risk groupings (high- or low-risk) for adverse outcomes for febrile neutropenia. Newly developed models underwent preliminary validation for their performance as prognostic models for febrile neutropenia outcomes. Background: Accuracy in risk stratification for cancer patients presenting with chemotherapy-induced febrile neutropenia is of critical importance. Serious morbidity may result when treatment is tailored according to misclassified levels of risk. New predictors and prediction tools used for risk stratification have been reported in the recent years. A systematic review was conducted on this topic as part of the thesis and the findings showed a lack of conclusive information on predictive values for some factors identified as predictors, and limitations in prognostic research studies’ methodologies which affect the internal and external validity of the risk prediction tools. Methods: Clinical factors identified through the systematic review contributed to the candidate factors investigated. Additional factors were also included based on other primary studies not included in the systematic review. A retrospective review of patients’ medical records was conducted. Tests of association using univariate analysis were conducted on these variables. Significant variables were tested and adjusted for confounders in a multivariate logistic regression analysis to formulate a multivariable tool for risk stratification of patients presenting with febrile neutropenia. Results: Predictive values for some variables were re-established while some variables failed to demonstrate their predictive values in a univariate analysis. After statistically adjusting to the current factors used in existing prognostic models, a new risk prediction tool was developed predict the risk of adverse outcomes. This tool has been subjected to preliminary validation that confirmed its potential utility. Limitations of the study included single-centre data and the small sample size. Conclusions: Application of a risk prediction tool has its benefits and limitations. However, enhancement of the methodological rigor and comprehensiveness of reporting of results in prognosis research needs to be emphasised for clarity in interpretation and implementation of the studies’ findings. Despite the promising initial validation of the tool developed in this thesis, further extensive validation and evaluation of the tool’s performance are needed to show the true impact of the tool on clinical practice.
Thesis (Ph.D.) -- University of Adelaide, School of Translational Health Science, 2014
APA, Harvard, Vancouver, ISO, and other styles
2

Liu, Cheng-Chung, and 劉承忠. "Study on the Use of G-CSF in Breast Cancer Patients for Managing Chemotherapy-induced Febrile Neutropenia." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/58531561954385730376.

Full text
Abstract:
碩士
臺北醫學大學
藥學研究所
97
Rationale Febrile neutropenia (FN) is a serious hematological toxicity of cancer chemotherapy and could be prevented with the prophylactic use of antibiotics and/or granulocyte colony-stimulating factor (G-CSF). G-CSF is hematopoietic growth-stimulating factor, which regulates the proliferation, differentiation and function of hematopoietic cells. G-CSF dose-dependently increases the cell number of circulating neutrophils. Early clinical trials indicated that primary prophylaxis with G-CSF reduces the duration of chemotherapy-induced neutropenia resulting in a 50% reduction in FN, infections, hospitalization, and the use of antibiotics in small cell lung cancer patients. In the study, the rate of FN was reduced from 77% to 40%, with long-term G-CSF treatment started on day 4 and continuing through day 17. Regarding to breast cancer patients, G-CSF as primary prophylaxis administered on days 4 to10 after TAC (adriamycin, paclitaxel, and cyclophosphamide) chemotherapy regimen lead to a reduction of FN risk from 27.5% to 7.5%. Based on the practice guidelines, primary prophylaxis of G-CSF treatment protocol can only be used for high risk patients with FN. Objective G-CSF is relatively expensive medicine. Currently, at the Sun Yat-Sen Cancer Center (SYSCC), G-CSF was prescribed to patients with prior severe neutropenia or FN for only three days due to the regulation of national health insurance (NHI). The main objective of this study was to investigate the rate of FN after primary and secondary prophylaxis of G-CSF in breast cancer patients (n=511); the secondary objectives were to investigate the prescribing pattern of G-CSF at SYSCC and to evaluate the cost-effectiveness of G-CSF use under the regulation of NHI. Study Design We performed a retrospective chart review of breast cancer patients who received chemotherapy or lenograstim at SYSCC during year 2007. The information included in this review were patients’ age, sex, tumor type, dosage of chemotherapy, the dose and duration of G-CSF, history of FN and neutropenia, and the length and cost of hospitalization due to FN. Then, we divided patients into three groups according to the risk of FN on received chemotherapy regimen, high (>20%), intermediate (10-20%), low (<10%), to find out the FN risk in different groups and also the regimen of lenograstim use. Furthermore, we focus on the FN risk and regimen of G-CSF use in patients with breast cancer who received chemotherapy regimen of TAC, ATC, and CAF. All these data will be analyzed and compared with the current literature to evaluate the efficacy and cost-effectiveness of G-CSF. Finally, a decision-analysis model was constructed from a health insurer’s perspective to evaluate the cost-effectiveness by considering direct medical costs only. The data required for the decision-analysis model were obtained from the medical literature and data from SYSCC. Results Between January 2007 and December 2007, 511 breast patients who received both chemotherapy and lenograstim at SYSCC were enrolled in the study. Patients in the high risk group (TAC) did not have significantly reduced rate of FN (33.33%) after receiving lenograstim treatment for 3 days. Furthermore, the three common chemotherapy regimens for the treatment of breast cancer were (i) sequential treatment with doxorubicin, paclitaxel, and cyclophosphamide (ATC), (ii) combined treatment with doxorubicin, docetaxel, and cyclophosphamide (TAC), and (iii) treatment with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF). Comparison of three treatment groups, group TAC (33.33%, with primary prophylaxis G-CSF) was associated with higher FN incidence than ATC (6.66%, with primary prophylaxis G-CSF) and CAF (5.97%, with secondary prophylaxis G-CSF) groups after 3 days lenograstim treatment. And the duration of lenograstim were 3.19 days in CAF group, 6.08 days in ATC group, and 2.95 days in TAC group, respectively. Finally, most of patients in the TAC and CAF groups received only 3 days of G-CSF prophylaxis due to the regulation of national health insurance (NHI). After the cost-effectiveness analysis, the incremental cost-effectiveness ratio (ICER) in comparison of 7-day treatment regimen (according to clinical trials) versus 3-day treatment regimen was unacceptably high (N.T.120,265 per FN episode avoided). Discussion The higher FN incidence in breast cancer patients of high risk chemotherapy regimen after G-CSF prophylaxis may be due to the short duration of G-CSF use. The risks of FN in TAC group of SYSCC and the prior study were 33.33% and 7.5%, respectively. This 5-fold higher risk in the TAC group may be due to the difference in period of G-CSF prophylaxis reducing from 7 days to 3 days in the SYSCC. In ATC group, the risk of FN in the present study (6.66%) was 3 times higher than the report of Citron et al. (2%). Earlier studies indicate the risk of developing FN in patients received CAF chemotherapy are ranging from 2 to 5 % while in the present study the risk was similar (5.97%). The reason of unexpected higher incidence of FN in TAC regimen is unclear, but is highly likely that the decreased efficacy was due to short time period (3 days) of G-CSF treatment. Concluding Remark Based on present results, patients who received chemotherapy of high risk in FN and G-CSF for primary prophylaxis still had the rate of FN 33.33%. The result may be due to the 3-day G-CSF use under the regulation of NHI. Moreover, many patients under 3-day G-CSF regimen may further require another 3-day G-CSF regimen to support the developed neutropenia. Additionally, the cost-effectiveness model provides evidence that 7-day G-CSF regimen is not only cost-effective but also cost-saving in clinical settings. There appeared to be both clinical and economic benefits from prophylaxis with standard administration (7-day) of G-CSF. Therefore, further prospective study should be performed to find out the most appropriate duration of G-SCF use. The result could be provided as an evidence to persuade and modify the reimbursement policy of NHI.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Chemotherapy-induced febrile neutropenia"

1

J, Klastersky, ed. Febrile neutropenia. Berlin: Springer, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Klastersky, J. Febrile neutropenia. London: Springer Healthcare, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Champigneulle, Benoit, and Frédéric Pène. Pathophysiology and management of neutropenia in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0274.

Full text
Abstract:
Neutropenia is defined by an absolute neutrophil count <500 per mm3. Chemotherapy-induced myelosuppression represents the main mechanism accounting for neutropenia, although various bone marrow disorders might also result in impaired granulopoiesis. Neutropenia, especially when profound and prolonged, is a major risk factor for severe bacterial and fungal infections. Early initiation of empirical broad-spectrum antibiotic therapy represents the cornerstone of the treatment of febrile neutropenia. A number of infected neutropenic patients may exhibit organ failures, such as acute respiratory failures and/or severe sepsis requiring intensive care unit (ICU) admission. This chapter discusses the particularities in the management of neutropenic patients in the ICU, including outcome and criteria for ICU admission, management of antimicrobials with respect to the current epidemiological trends, and other measures specific to this subgroup of patients.
APA, Harvard, Vancouver, ISO, and other styles
4

Howe, Christine K. An assessment of an antibiotic treatment algorithm for chemotherapy-induced febrile neutropenia: prescribing congruence and patient outcomes. 2003, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Chemotherapy-induced febrile neutropenia"

1

Rivera, F., J. I. Mayordomo, M. T. Díaz-Puente, M. P. Lianes, M. López-Brea, E. López, L. Paz-Ares, S. Alonso, and H. Cortés-Funes. "Role of G-CSF and GM-CSF in the treatment of febrile neutropenia induced by chemotherapy ; preliminary results of a randomized trial." In Cancer Treatment An Update, 880–84. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yadav, SP, and A. Sachdeva. "Granulocyte Colony-Stimulating Factor (G-CSF) for Chemotherapy-Induced Febrile Neutropenia." In Advances in Pediatrics, 471. Jaypee Brothers Medical Publishers (P) Ltd., 2007. http://dx.doi.org/10.5005/jp/books/10034_51.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yap, Kevin Yi-Lwern. "A Pharmaco-Cybernetics Approach to Patient Safety." In Healthcare Ethics and Training, 1291–310. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-2237-9.ch061.

Full text
Abstract:
Pharmaco-cybernetics is an upcoming interdisciplinary field that supports our use of medicines and drugs through the combined use of computational technologies and techniques with human-computer-environment interactions to reduce or prevent drug-related problems. The advent of pharmaco-cybernetics has led to the development of various software, tools, and Internet applications that can be used by healthcare practitioners to deliver optimum pharmaceutical care and health-related outcomes. Patients are becoming more informed through health information on the Internet, which empowers them to better participate in the management of their own conditions. Focusing on patients with cancer, this chapter describes the use of a pharmaco-cybernetics approach to identify clinically relevant predictors of two debilitating adverse drug reactions, which are a cause of patient safety – chemotherapy-induced nausea and vomiting and febrile neutropenia. The early identification of such clinical predictors enables clinicians to prevent or reduce the occurrence of adverse drug reactions in cancer patients undergoing chemotherapy through appropriate management strategies. The computational methods used in this approach involve two unsupervised machine-learning techniques – principal component and multiple correspondence analyses. Using two case examples, this chapter shows the potential of machine-learning techniques for identifying patients who are at greater risks of these adverse drug reactions, thus enhancing patient safety. This chapter also aims to increase the awareness among healthcare professionals and clinician-scientists about the usefulness of such techniques in clinical patient populations, so that these can be considered as part of clinical care pathways to enhance patient safety and effectively manage cancer patients on chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
4

Yap, Kevin Yi-Lwern. "A Pharmaco-Cybernetics Approach to Patient Safety." In E-Health and Telemedicine, 1445–64. IGI Global, 2016. http://dx.doi.org/10.4018/978-1-4666-8756-1.ch073.

Full text
Abstract:
Pharmaco-cybernetics is an upcoming interdisciplinary field that supports our use of medicines and drugs through the combined use of computational technologies and techniques with human-computer-environment interactions to reduce or prevent drug-related problems. The advent of pharmaco-cybernetics has led to the development of various software, tools, and Internet applications that can be used by healthcare practitioners to deliver optimum pharmaceutical care and health-related outcomes. Patients are becoming more informed through health information on the Internet, which empowers them to better participate in the management of their own conditions. Focusing on patients with cancer, this chapter describes the use of a pharmaco-cybernetics approach to identify clinically relevant predictors of two debilitating adverse drug reactions, which are a cause of patient safety – chemotherapy-induced nausea and vomiting and febrile neutropenia. The early identification of such clinical predictors enables clinicians to prevent or reduce the occurrence of adverse drug reactions in cancer patients undergoing chemotherapy through appropriate management strategies. The computational methods used in this approach involve two unsupervised machine-learning techniques – principal component and multiple correspondence analyses. Using two case examples, this chapter shows the potential of machine-learning techniques for identifying patients who are at greater risks of these adverse drug reactions, thus enhancing patient safety. This chapter also aims to increase the awareness among healthcare professionals and clinician-scientists about the usefulness of such techniques in clinical patient populations, so that these can be considered as part of clinical care pathways to enhance patient safety and effectively manage cancer patients on chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
5

Yap, Kevin Yi-Lwern. "A Pharmaco-Cybernetics Approach to Patient Safety." In Advances in Healthcare Information Systems and Administration, 179–97. IGI Global, 2014. http://dx.doi.org/10.4018/978-1-4666-4546-2.ch010.

Full text
Abstract:
Pharmaco-cybernetics is an upcoming interdisciplinary field that supports our use of medicines and drugs through the combined use of computational technologies and techniques with human-computer-environment interactions to reduce or prevent drug-related problems. The advent of pharmaco-cybernetics has led to the development of various software, tools, and Internet applications that can be used by healthcare practitioners to deliver optimum pharmaceutical care and health-related outcomes. Patients are becoming more informed through health information on the Internet, which empowers them to better participate in the management of their own conditions. Focusing on patients with cancer, this chapter describes the use of a pharmaco-cybernetics approach to identify clinically relevant predictors of two debilitating adverse drug reactions, which are a cause of patient safety – chemotherapy-induced nausea and vomiting and febrile neutropenia. The early identification of such clinical predictors enables clinicians to prevent or reduce the occurrence of adverse drug reactions in cancer patients undergoing chemotherapy through appropriate management strategies. The computational methods used in this approach involve two unsupervised machine-learning techniques – principal component and multiple correspondence analyses. Using two case examples, this chapter shows the potential of machine-learning techniques for identifying patients who are at greater risks of these adverse drug reactions, thus enhancing patient safety. This chapter also aims to increase the awareness among healthcare professionals and clinician-scientists about the usefulness of such techniques in clinical patient populations, so that these can be considered as part of clinical care pathways to enhance patient safety and effectively manage cancer patients on chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Chemotherapy-induced febrile neutropenia"

1

Tsuchida, Shinpei, Hironobu Tsubouchi, Akiko Kitamura, Nobuhiro Matsumoto, and Masamitsu Nakazato. "Risk factors of febrile neutropenia induced by chemotherapy in lung cancer patients." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa4842.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Myers, R., B. Higgins, J. Myers, M. Leung, S. Rajagopal, G. Jones, and J. Stakiw. "Chemotherapy Induced Febrile Neutropenia of Docetaxel with Cyclophosphamide (TC) for Adjuvant Therapy of Breast Cancer in the Community – Reality Check." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-2092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Weycker, Derek, Xiaoyan Li, Richard Barron, Hongsheng Wu, Phuong Khanh Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani Mhatre, and Gary Lyman. "Abstract P6-10-01: Risk of chemotherapy-induced febrile neutropenia (FN) in patients (pts) with non-metastatic breast cancer (BC) and documented risk factors for FN." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p6-10-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

McBride, A., K. Campbell, M. Bikkina, K. MacDonald, I. Abraham, and S. Balu. "Abstract P4-12-07: Cost-minimization of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar ZARXIO® over NEUPOGEN®, NEULASTA®, and NEULASTA/ONPRO®: Breast cancer case study." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p4-12-07.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gascón, Pere, Matti Aapro, Heinz Ludwig, Mario Boccadoro, Carsten Bokemeyer, Matthew Turner, Michael Muenzberg, Ivo Abraham, Kris Denhaerynck, and Karen MacDonald. "Abstract P5-15-19: Prophylaxis of chemotherapy-induced febrile neutropenia with biosimilar filgrastim: Description of patients, treatment patterns and outcomes in the MONITOR-GCSF study in the breast cancer cohort." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p5-15-19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Weycker, Derek, Amanda Silvia, Ahuva Hanau, Lois Lamerato, Kathryn Richert-Boe, Manpreet Kaur, Neel Shah, Mark Hatfield, and Gary H. Lyman. "Abstract P2-08-24: Risk of chemotherapy-induced febrile neutropenia (FN) in patients with metastatic cancer of the breast or other sites not receiving colony-stimulating factor prophylaxis (CSF) in US clinical practice." In Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-p2-08-24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Chemotherapy-induced febrile neutropenia' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography